Biotech Values

[pollyvonwog]

TEVA thinks they could nab 30% (from an analyst report I get):

"Our conversations with Teva management as well as physicians indicate that around 30% of the Copaxone franchise could be converted to the less frequent dosing regimen should it ultimately receive FDA approval."

It goes on to say that they expect TEVA to file for approval this year, FWIW.